‘Oku taupotu ‘i lalo ha fakamatala fakaTonga
Scientists in New Zealand are running a trial of a combined vaccine for both flu and Covid-19.
The Wellington P3 Research experts believes the combined vaccine will reduce the workload for healthcare services.
The company was looking for people aged between 50 and 80 years old to take part in the clinical trial, which is investigating whether the single vaccine can effectively prevent both illnesses.
The company conducted research on behalf of a range of pharmaceutical companies, including Pfizer and AstraZeneca – two major Covid-19 vaccine manufacturers.
Covid-19 and influenza were among the more common viruses leading to severe illness and hospitalisation in older adults, P3 Research said, and currently individual vaccinations provided the best protection against each disease.
As well as the age requirement, it was looking for participants who were in good health, and were fully vaccinated against Covid-19 (with or without the booster).
They must not have had a Covid-19 infection in the last two months.
The study would require willing participants to receive a vaccination and then attend follow-up appointments for six months.
The new research in New Zealand came after scientists in the US were working on a shot that could protect against Covid-19, its variants, certain seasonal colds ā and the next coronavirus pandemic.
The US researchers were starting to develop prototypes of a so-called pancoronavirus vaccine, with some promising, if early, results from experiments on animals. Dr. Eric Topol, a professor of molecular medicine at the Scripps Research Institute in San Diego, thinks scientists should join together in another large-scale vaccine-creation project immediately.
āWe have to get a real work force to accelerate this, so we can have it this year,ā he said. Dr. Topol and Dennis Burton, a Scripps immunologist, called for thisĀ project on broad coronavirus vaccinesĀ on Monday in the journal Nature.
FAKAMATALA FAKATONGA
Kamata āa hono tesiāi āi Nuāu Sila ha faitoāo huhu maluāi e lava ke fakatahaāi pe ai āa e faitoāo ki he Kovitiā mo e Fuluuā.
Ko e ngÄueā ni āoku fakahoko āe he kau mataotao mei he kautaha Wellinton P3 Research āa ia āoku nau tui āe maāamaāa ange heni āa e ngÄueā.
āOku fai āa e fakatotoloā ni fakafofongaāi ai āa e ngaahi kautaha āoku nau tuāuaki āa e faitoāo hangÄ ko e Pfizer mo e AstraZeneca ā āa ia ko e ongo kautaha lalahi ia āoku na faāu āa e huhu maluāi Kovitiā.
Ko e kakai ko āeni āoku tesiāi ai āa e faitoāo ko eni ko e kakai pe āoku nau moāui lelei, āosi huhu maluāi kakato mei he Koviti āo tatau pe pe kuo nau āosi hoani pe āikai.
Ko e hu mai āeni āa e huhu maluāiā ni hili ia ha ngaue āa e kau saienisi āAmelikaā ki ha huhu maluāi te ne lava maluāi āa e Koviti, hono ngaahi fÅtunga kehe, ngaahi mahaki pau āo e faāahitaāu Momoko pea mo e vailasi kolona.
Naāe faāu au āe he kau fakatotolo āAmelika ha polototaipe āa ia ko e vekisini ne sai āaupito ia āa ia ko e ola ia āo ha āahiāahi āi he monumanuā.